FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
Fibrinogen-like protein 2 (FGL2) mediates immune suppression in glioblastoma (GBM). Here, the authors show that FGL-2 expressed by GBM cancer cells acts by suppressing the differentiation of CD103+ DC cells required to activate the anti-tumor CD8+ T cell response via blocking GM-CSF signalling at NF...
Main Authors: | Jun Yan, Qingnan Zhao, Konrad Gabrusiewicz, Ling-Yuan Kong, Xueqing Xia, Jian Wang, Martina Ott, Jingda Xu, R. Eric Davis, Longfei Huo, Ganesh Rao, Shao-Cong Sun, Stephanie S. Watowich, Amy B. Heimberger, Shulin Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2019-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-018-08271-x |
Similar Items
-
Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
by: Jun Yan, et al.
Published: (2019-02-01) -
The Controversial Role of Microglia in Malignant Gliomas
by: Jun Wei, et al.
Published: (2013-01-01) -
FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells
by: Qingnan Zhao, et al.
Published: (2023-02-01) -
FGL1 and FGL2: emerging regulators of liver health and disease
by: Jiongming Chen, et al.
Published: (2024-05-01) -
Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells
by: Eugenie S Kleinerman, et al.
Published: (2020-05-01)